Form 4: Parkman Healthcare Adjusts SPRB Holdings

Parkman Healthcare Partners LLC reported both acquisitions and disposals of Spruce Biosciences common stock, adjusting its indirect beneficial ownership.

Summary

• Parkman Healthcare Partners LLC, identified as a 10% owner of Spruce Biosciences, Inc. (SPRB), filed a Form 4 detailing recent transactions.
• The reported transactions occurred on October 6, 2025.
• Parkman Healthcare Partners LLC acquired 256 shares of Spruce Biosciences common stock at a weighted average price of $17.9108 per share.
• The entity disposed of 232 shares of common stock at a weighted average price of $19.3264 per share.
• An additional 25 shares were disposed of at a weighted average price of $17.4557 per share.
• Following these transactions, the reporting person indirectly beneficially owns 1,050 shares of Spruce Biosciences common stock.
• The ownership is held through an investment in private funds, and beneficial ownership is disclaimed except to the extent of pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions with a very small net change in holdings, indicating a neutral sentiment. There are both acquisitions and disposals, balancing the overall impact.

Positives

• Acquisition of 256 shares of common stock indicates continued investment interest in Spruce Biosciences.
• Sale of 232 shares at a weighted average price of $19.3264, which is higher than the acquisition price of $17.9108, suggests a profitable divestment for that specific block of shares.

Negatives

• A net reduction of 1 share in beneficial ownership (256 acquired vs. 257 disposed) occurred across the reported transactions.
• Sale of 25 shares at a weighted average price of $17.4557, which is lower than the acquisition price of $17.9108, indicates a potential loss on that specific block of shares.

Future Outlook

The filing does not provide any forward-looking statements or guidance.

Management Comments

• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• A subsequent Form 4 will be filed for Gregory Martinez once CIK codes are received.

Industry Context

Form 4 filings provide transparency into insider trading activities, offering insights into how company insiders and significant shareholders view the company's prospects. While these transactions are routine, they can sometimes signal management's confidence or concerns, though the net change in this specific filing is minimal.

Stakeholder Impact

• Shareholders: Provides transparency on a 10% owner's trading activity, which could be interpreted as a minor adjustment in conviction, though the net change is negligible.

Next Steps

• A subsequent Form 4 will be filed for Gregory Martinez once CIK codes are received.

Key Dates

Recommendation

The filing details routine insider transactions by a 10% owner, Parkman Healthcare Partners LLC, involving both acquisitions and disposals of Spruce Biosciences common stock. The net change in beneficial ownership is a negligible decrease of 1 share. Such minor adjustments by a significant shareholder typically do not warrant a change in investment thesis. The transactions do not provide strong signals for either buying or selling, thus a 'hold' recommendation is appropriate as it suggests maintaining current positions while awaiting more substantial operational or financial news.

Keywords

Spruce Biosciences, SPRB, Parkman Healthcare Partners, Form 4, Insider Trading, Beneficial Ownership, Stock Transaction, Equity Holdings